Glioblastoma Multiforme
426
57
88
189
Key Insights
Highlights
Success Rate
75% trial completion
Published Results
85 trials with published results (20%)
Research Maturity
189 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.8%
63 terminated out of 426 trials
75.0%
-11.6% vs benchmark
4%
17 trials in Phase 3/4
45%
85 of 189 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 189 completed trials
Clinical Trials (426)
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM
A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
Collection of Blood and Urine Samples in Patients Receiving Radiation Therapy for Glioblastoma Multiforme
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
Neurosurgical Neuronavigation Using Resting State MRI and Machine Learning
Subventricular Zone (SVZ) and Temozolomide in Glioblastoma Multiforme
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors